Myriad
In Brief This Week: Qiagen, Oncocyte, Myriad Genetics, Mesa Biotech, and More
News items for the in vitro diagnostics industry for the week of May 31, 2021.
Myriad Genetics Sells Pharma Research Services Business to Q2 Solutions
The divestiture is part of Myriad's plan to restructure its business and get itself back on stronger financial footing.
During an "Investor Day" presentation, company executives presented plans for growing test volumes, increasing market share, and expanding access to underserved populations.
Myriad Genetics' Quarterly Revenues Increase 6 Percent
For the three months ended March 31, the firm reported total revenues of $173.1 million, beating the consensus Wall Street estimate.
Labcorp to Acquire Myriad Genetics' Vectra Rheumatoid Arthritis Test for $150M
The deal for the blood-based proteomic test, which measures disease activity in patients with rheumatoid arthritis, is expected to close in Q3 2021.